Pulmonary patients

Pulmonary Safety in

Pulmonary Safety pr

Not known pulmonary hypertension.

Pulmonary complications

Epistaxis Pulmonary haemorrhage

Flushing Pulmonary embolism

Pulmonary haemorrhage Uncommon

Pulmonary artery hypertension

Pulmonary eosinophilia

Pulmonary hypertension Pulmonary hypertension is a known complication of Gaucher disease.

Pulmonary hypertension Pulmonary hypertension is a known complication of Gaucher disease.

hypertension).

5 Pulmonary veno occlusive disease

23 Pulmonary veno occlusive disease

Very rare cough, pulmonary hypertension

Cardiac disorders Common congestive heart failure cardiac dysfunction, pericardial effusion, arrhythmia (including tachycardia), palpitations Uncommon myocardial infarction, pericarditis, ventricular arrhythmia (including ventricular tachycardia), angina pectoris, cardiomegaly Rare cor pulmonale, myocarditis, acute coronary syndrome

Embolism pulmonary, oedema, oedema peripheral

Skin and subcutaneous tissue disorders Very common

Deep venous thrombosis and pulmonary embolism

Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.

In normal donors, pulmonary adverse events (haemoptysis, pulmonary haemorrhage, pulmonary infiltrates, dyspnoea and hypoxia) have been reported very rarely in post marketing experience (see section 4.4).

In normal donors, pulmonary adverse events (haemoptysis, pulmonary haemorrhage, pulmonary infiltrates, dyspnoea and hypoxia) have been reported very rarely in post marketing experience (see section 4.4).

However, since a significant percentage of these patients were

However, since a significant percentage of these patients were

Interstitial lung disease (including pneumonitis and pulmonary fibrosis)

Acute diffuse infiltrative pulmonary and pericardial disease.

In normal donors, pulmonary adverse events (haemoptysis, pulmonary haemorrhage, pulmonary infiltrates, dyspnoea and hypoxia) have been reported very rarely in post marketing experience.

Pulmonary events Severe pulmonary events have been reported rarely with the use of Herceptin in the post marketing setting (see 4.8).

Gastrointestinal disorders

Pulmonary changes As with other alpha interferons, pulmonary symptoms, including dyspnoea, pulmonary infiltrates, pneumonia, and pneumonitis have been reported during therapy with Pegasys.

References External links Emedicine The Merck Manual of Diagnosis and Therapy Cor Pulmonale

Nasal septum perforation (not known)

When inhaled, nitric oxide produces pulmonary vasodilation.

Mean pulmonary systolic blood pressure decreased by 9 .

Palpitations, tachycardia Cardiac failure, cardiomegaly, cor pulmonale, sinus arrest, supraventricular extrasystoles, tricuspid valve incompetence

Very common abnormal breath sounds, abnormal chest sounds, cough Common shortness of breath, pulmonary interstitial infiltrates mostly due to infectious aetiology, mucositis Uncommon pharyngitis Very rare lung embolism

Viral infection, pharyngitis Fungal infection, bacterial infection, pulmonary infection, otitis media, tooth abscess, herpes simplex, urinary tract infection,

Viral infection, pharyngitis Fungal infection, bacterial infection, pulmonary infection, otitis

disease, pulmonary hypertension, respiratory failure, pulmonary alveolar haemorrhage, acute pulmonary oedema, pulmonary oedema, pulmonary embolism, peripheral embolism

Rare pulmonary undesirable effects including interstitial pneumonia, pulmonary oedema and pulmonary infiltrates have been reported in some cases with an outcome of respiratory failure or adult respiratory distress syndrome (ARDS) which may be fatal (see section 4.4).

It was first identified by Ernst von Romberg in 1891.

Pulmonary embolism, dyspnoea , exertional dyspnoea, bronchitis, cough, pharyngitis, nasopharyngitis, hoarseness, hiccups, epistaxis

Pulmonary artery hypertension is a severe and often fatal disease.

An epidemiological study has snown that anorectic intake is a risk factor involved in the